Centauri Therapeutics

Centauri Therapeutics is a private, clinical-stage biotech leveraging its proprietary Alphamer technology to create immunotherapies for infectious diseases and oncology. Its lead programs target Gram-negative bacterial infections, a critical area of antimicrobial resistance (AMR), and have attracted significant non-dilutive funding from CARB-X and investment from the AMR Action Fund. With its lead candidate advancing towards first-in-human trials and having received FDA QIDP designation, the company is positioned to address high-unmet-need infections in immunocompromised and vulnerable patients.

Proprietary Alphamer technology: synthetic bifunctional molecules that redirect pre-existing, naturally occurring antibodies in the patient's body to bind to and eliminate pathogens or cancer cells, leveraging a clinically validated immune effector mechanism.

Centauri competes in the novel anti-infective space with companies developing phage therapies, monoclonal antibodies, and other virulence inhibitors. In immuno-oncology, it would face competition from established modalities like checkpoint inhibitors, CAR-T, and bispecific antibodies. Its key differentiation is the mechanism of redirecting pre-existing antibodies, which may offer advantages in speed of action and applicability in immunocompromised patients.